Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer

被引:68
|
作者
Zaravinos, Apostolos [1 ,2 ]
Roufas, Constantinos [1 ,3 ]
Nagara, Majdi [4 ]
de Lucas Moreno, Beatriz [1 ,5 ]
Oblovatskaya, Maria [1 ]
Efstathiades, Christodoulos [2 ,3 ]
Dimopoulos, Christos [2 ,3 ]
Ayiomamitis, Georgios D. [6 ]
机构
[1] European Univ Cyprus, Sch Sci, Dept Life Sci, CY-1516 Nicosia, Cyprus
[2] Ctr Risk & Decis Sci CERIDES, CY-2404 Nicosia, Cyprus
[3] European Univ Cyprus, Dept Comp Sci & Engn, CY-1516 Nicosia, Cyprus
[4] Aix Marseille Univ, Fac Med, INSERM, UMR S 1251,MMG, Marseille, France
[5] European Univ Madrid, Ctr Res Hlth & Life Sci, Madrid 28670, Spain
[6] Tzane Gen Hosp, Surg Dept 1, Piraeus 18536, Greece
关键词
Colorectal cancer; Cytolytic activity; Classically defined neoepitopes; Alternatively defined neoepitopes; Mutation burden; Immune checkpoints; Cancer drivers; CD8(+) T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; MISMATCH REPAIR DEFICIENCY; MICROSATELLITE INSTABILITY; ANTI-PD-L1; ANTIBODY; GENOMIC INSTABILITY; CLINICAL IMPACT; SOLID TUMORS; COLON; SURVIVAL;
D O I
10.1186/s13046-019-1372-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundMicrosatellite unstable colorectal cancers (MSI+ CRCs) expressing PD-L1, respond to anti-PD-1 or anti-PD-L1 checkpoint blockade, whereas microsatellite-stable tumors do not respond the same. Our aim was to examine how the immune landscape relates to different aspects of the CRC's biology, including neoepitope burden.MethodsWe used TCGA data to stratify patients based on a cytolytic T-cell activity expression index and correlated immune cytolytic activity (CYT) with mutational, structural, and neoepitope features of each tumor sample. The expression of several immune checkpoints was verified in an independent cohort of 72 CRC patients, relative to their MSI status, using immunohistochemistry and RT-qPCR.ResultsCRC exhibits a range of intertumoral cytolytic T-cell activity, with lower cytolytic levels in the tumor, compared to the normal tissue. We separated CRC patients into CYT-high and CYT-low subgroups. High cytolytic activity correlated with increased mutational load in colon tumors, the count of MHC-I/-II classically defined and alternatively defined neoepitopes, high microsatellite instability and deregulated expression of several inhibitory immune checkpoints (VISTA, TIGIT, PD-1, IDO1, CTLA-4, and PD-L1, among others). Many immune checkpoint molecules (IDO1, LAG3, TIGIT, VISTA, PD-1, PD-L1 and CTLA-4) expressed significantly higher in MSI+ CRCs compared to MSS tumors. The expression of Treg markers was also significantly higher in CYT-high tumors. Both individual and simultaneous high levels of CTLA-4 and PD-L1 had a positive effect on the patients' overall survival. On the reverse, simultaneous low expression of both genes led to a significant shift towards negative effect. Assessed globally, CYT-low CRCs contained more recurrent somatic copy number alterations. PD-L1 protein was absent in most samples in the independent cohort and stained lowly in 33% of MSI CRCs. PD-L1+ CRCs stained moderately for CD8 and weakly for FOXP3. CYT-high colon tumors had higher TIL load, whereas CYT-high rectum tumors had higher TAN load compared to their CYT-low counterparts.ConclusionsOverall, we highlight the link between different genetic events and the immune microenvironment in CRC, taking into consideration the status of microsatellite instability. Our data provide further evidence that MSI+ and CYT-high tumors are better candidates for combinatorial checkpoint inhibition.
引用
收藏
页数:18
相关论文
共 50 条
  • [11] Aluminum Concentration Is Associated with Tumor Mutational Burden and the Expression of Immune Response Biomarkers in Colorectal Cancers
    Bonfiglio, Rita
    Giacobbi, Erica
    Palumbo, Valeria
    Casciardi, Stefano
    Sisto, Renata
    Servadei, Francesca
    Scioli, Maria Paola
    Schiaroli, Stefania
    Cornella, Elena
    Cervelli, Giulio
    Sica, Giuseppe
    Candi, Eleonora
    Melino, Gerry
    Mauriello, Alessandro
    Scimeca, Manuel
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (24)
  • [12] Modulation of Immune System Inhibitory Checkpoints in Colorectal Cancer
    Patel, Sandip P.
    Osada, Takuya
    Osada, Koya
    Hurwitz, Herbert
    Lyerly, H. Kim
    Morse, Michael A.
    CURRENT COLORECTAL CANCER REPORTS, 2013, 9 (04) : 391 - 397
  • [13] Targeting Immune Checkpoints in Esophageal Cancer: A High Mutational Load Tumor
    Dhupar, Rajeev
    Van der Kraak, Lauren
    Pennathur, Arjun
    Schuchert, Matthew J.
    Nason, Katie S.
    Luketich, James D.
    Lotze, Michael T.
    ANNALS OF THORACIC SURGERY, 2017, 103 (04): : 1340 - 1349
  • [14] Mutational landscapes and tumour mutational burden expression in endometrial cancer
    Zhang, Y.
    Zhang, J.
    Shao, Z.
    Zhao, L.
    Zhang, Y.
    Zhang, S.
    Zhao, S.
    Guo, F.
    Pang, F.
    Zhang, L.
    Dong, X.
    Wang, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [15] Tumor mutational burden in colorectal cancer: Implications for treatment
    Marques, Adriana
    Cavaco, Patricia
    Torre, Carla
    Sepodes, Bruno
    Rocha, Joao
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 197
  • [16] Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer
    Jones, Nathaniel L.
    Xiu, Joanne
    Rocconi, Rodney P.
    Herzog, Thomas J.
    Winer, Ira S.
    GYNECOLOGIC ONCOLOGY, 2020, 156 (02) : 393 - 399
  • [17] Immune checkpoint expression, microsatellite instability, and mutational burden: Identifying immune biomarker phenotypes in uterine cancer
    Jones, N. L.
    Xiu, J.
    Herzog, T.
    Winer, I.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 44 - 44
  • [18] Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer
    Reem Saleh
    Rowaida Z. Taha
    Salman M. Toor
    Varun Sasidharan Nair
    Khaled Murshed
    Mahwish Khawar
    Mahmood Al-Dhaheri
    Mahir Abdulla Petkar
    Mohamed Abu Nada
    Eyad Elkord
    Cancer Immunology, Immunotherapy, 2020, 69 : 1989 - 1999
  • [19] Expression of immune checkpoints and T cell exhaustion markers in early and advanced stages of colorectal cancer
    Saleh, Reem
    Taha, Rowaida Z.
    Toor, Salman M.
    Nair, Varun Sasidharan
    Murshed, Khaled
    Khawar, Mahwish
    Al-Dhaheri, Mahmood
    Petkar, Mahir Abdulla
    Abu Nada, Mohamed
    Elkord, Eyad
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2020, 69 (10) : 1989 - 1999
  • [20] Relationship between ICOS and ICOS ligand RNA expression patterns with tumor type, tumor mutational burden, and clinically relevant immune checkpoints
    Nikanjam, Mina
    Kato, Shumei
    Nishizaki, Daisuke
    Barkauskas, Donald A.
    Pabla, Sarabjot
    Nesline, Mary K.
    Conroy, Jeffrey M.
    Naing, Aung
    Kurzrock, Razelle
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)